OMB APPROVAL | |
OMB Number | 3235-0145 |
Expires: | December 31, 2005 |
Estimated average burden hours per response ..... 11 |
o
|
Rule 13d-1(b)
|
x
|
Rule 13d-1(c)
|
o
|
Rule 13d-1(d)
|
1 |
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Bristol Investment Fund, Ltd. (98-0335509)
|
|||
2
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) o
(b) o
|
|||
3
|
SEC Use Only
|
|||
4
|
Citizenship or Place of Organization
Cayman Islands
|
|||
Number of Shares
Beneficially Owned by Each Reporting Person With: |
5
|
Sole Voting Power
897,621 shares of common stock*
*plus shares underlying $3,056,006.67 of principal amount of convertible instruments
and warrants to purchase 2,500,238,718 shares of common stock, neither of which may be
converted into more than 1% of Common Stock
|
||
6
|
Shared Voting Power
|
|
||
7
|
Sole Dispositive Power
897,621 shares of common stock*
*plus shares underlying $3,056,006.67 of principal amount of convertible instruments
and warrants to purchase 2,500,238,718 shares of common stock, neither of which may be
converted into more than 1% of Common Stock
|
|||
8
|
Shared Dispositive Power
|
|
||
9
|
Aggregate Amount Beneficially Owned by Each Reporting Person
897,621 shares of common stock*
*plus shares underlying $3,056,006.67 of principal amount of convertible instruments and warrants to purchase 2,500,238,718 shares of common stock, neither of which may be converted into more than 1% of Common Stock
|
|||
10
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) o
|
|||
11
|
Percent of Class Represented by Amount in Row (9)
1.0%
|
|||
12
|
Type of Reporting Person (See Instructions)
CO
|
(a)
|
Name of Issuer:
Radient Pharmaceuticals Corporation
|
(b)
|
Address of Issuer's Principal Executive Offices:
2492 Walnut Avenue, Suite 100, Tustin, California 92780-70391
|
(a)
|
Name of Person Filing:
Bristol Investment Fund, Ltd. (98-0335509)
|
(b)
|
Address of Principal Business Office, or if None, Residence:
Caledonian Trust (Cayman) Limited, 69 Dr. Roy’s Drive, P.O. Box 1043, Grand Cayman KY1-1102
|
(c)
|
Citizenship:
Cayman Islands
|
(d)
|
Title of Class of Securities:
Common Stock
|
(e)
|
CUSIP Number:
750341109
|
(a)
|
o Broker or dealer registered under Section 15 of the Act(15 U.S.C. 78o).
|
(b)
|
o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
|
(c)
|
o Insurance company as defined in Section 3(a)(19) of the Act (15U.S.C. 78c).
|
(d)
|
o Investment company registered under Section 8 of the InvestmentCompany Act of 1940 (15 U.S.C. 80a-8).
|
(e)
|
o An investment adviser in accordance withss.240.13d-1(b)(1)(ii)(E);
|
(f)
|
o An employee benefit plan or endowment fund in accordance withss.240.13d-1(b)(1)(ii)(F);
|
(g)
|
o A parent holding company or control person in accordance withss.240.13d-1(b)(1)(ii)(G);
|
(h)
|
o A savings associations as defined in Section 3(b) of the FederalDeposit Insurance Act (12 U.S.C. 1813);
|
(i)
|
o A church plan that is excluded from the definition of aninvestment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
(j)
|
o Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
|
(a)
|
Amount beneficially owned: 897,621 shares of common stock*
*plus shares underlying $3,056,006.67 of principal amount of convertible instruments and warrants
to purchase 2,500,238,718 shares of common stock, neither of which may be converted into more than 1%
of the Issuer's outstanding common stock
|
(b)
|
Percent of class: 1.0%
|
(c)
|
Number of shares as to which such person has:
|
(i)
|
Sole power to vote or to direct the vote
897,621 shares of common stock*
*plus shares underlying $3,056,006.67 of principal amount of convertible instruments and warrants
to purchase 2,500,238,718 shares of common stock, neither of which may be converted into more than 1%
of the Issuer's outstanding common stock
|
(ii)
|
Shared power to vote or to direct the vote
|
(iii)
|
Sole power to dispose or to direct the disposition of
897,621 shares of common stock*
*plus shares underlying $3,056,006.67 of principal amount of convertible instruments and warrants
to purchase 2,500,238,718 shares of common stock, neither of which may be converted into more than 1%
of the Issuer's outstanding common stock
|
(iv)
|
Shared power to dispose or to direct the disposition of
|
(a)
|
The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b):
|
(b)
|
The following certification shall be included if the statement isfiled pursuant to Rule 13d-1(c):
|
February 14, 2012
|
||
(Date) | ||
/s/ PAUL KESSLER | ||
(Signature) | ||
Paul Kessler, Director | ||
(Name/Title) |